Cover Image

Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC

Background and objectiveSintilimab has superior efficacy and safety in patients with advanced or metastatic squamous non-small cell lung cancer (NSCLC), but its cost-effectiveness in China is unclear. This study is to evaluate the cost-effectiveness of sintilimab plus chemotherapy vs. pembrolizumab...

Full description

Saved in:

Bibliographic Details
Main Authors:	Pingyu Chen (Author), Xintian Wang (Author), Shengwen Zhu (Author), Hongchao Li (Author), Mingjun Rui (Author), Yingcheng Wang (Author), Haikui Sun (Author), Aixia Ma (Author)
Format:	Book
Published:	Frontiers Media S.A., 2022-08-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Cost-effectiveness analysis of sintilimab plus bevacizumab biosimilar compared with lenvatinib as the first-line treatment of unresectable or metastatic hepatocellular carcinoma
by: Ting Zhou, et al.
Published: (2022)

Cost-Effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in Metastatic Non-Squamous and Squamous NSCLC Patients With PD-L1 Expression ≥ 50%
by: Qiao Liu, et al.
Published: (2022)

Economic Evaluation of First-Line Atezolizumab for Extensive-Stage Small-Cell Lung Cancer in the US
by: Yingcheng Wang, et al.
Published: (2021)

Economic Burden of Myocardial Infarction Combined With Dyslipidemia
by: Pingyu Chen, et al.
Published: (2021)

Cost-effectiveness analysis of first-line sintilimab plus chemotherapy vs. chemotherapy alone for unresectable advanced or metastatic gastric or gastroesophageal junction cancer in China
by: Zuojuan Xiang, et al.
Published: (2024)

Cost-effectiveness of pembrolizumab plus chemotherapy vs. chemotherapy as first-line treatment for advanced biliary tract cancer in China and the US
by: Xianmei Luo, et al.
Published: (2024)

First-line sintilimab plus chemotherapy in locally advanced or metastatic esophageal squamous cell carcinoma: A cost-effectiveness analysis from China
by: Jian Shen, et al.
Published: (2022)

Cost-effectiveness analysis of camrelizumab plus paclitaxel and carboplatin versus sintilimab plus gemcitabine and cisplatin or carboplatin for the first-line treatment of local advanced or metastatic squamous NSCLC in Chinese mainland
by: Xiaoting Liu, et al.
Published: (2024)

Successful neoadjuvant chemotherapy plus sintilimab for locally advanced cervical cancer: case series and review of the literature
by: Linlin Liu, et al.
Published: (2023)

Cost-Effectiveness of Pembrolizumab Plus Chemotherapy as First-Line Therapy for Advanced Oesophageal Cancer
by: Meiyu Wu, et al.
Published: (2022)

Atezolizumab plus bevacizumab and chemotherapy versus bevacizumab plus chemotherapy for metastatic cervical cancer: a cost-effectiveness analysis
by: Hongfu Cai, et al.
Published: (2024)

Lenvatinib Plus Pembrolizumab vs. Chemotherapy in Pretreated Patients With Advanced Endometrial Cancer: A Cost-Effectiveness Analysis
by: Mingyang Feng, et al.
Published: (2022)

Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer in China
by: Zhang X, et al.
Published: (2023)

Sugemalimab plus chemotherapy vs. chemotherapy for metastatic non-small-cell lung cancer: A cost-effectiveness analysis
by: Xueyan Liang, et al.
Published: (2023)

Nivolumab plus ipilimumab with chemotherapy in metastatic NSCLC: minireview and a case study of a patient negative for PD-L1
by: Alessandro Morabito
Published: (2024)

Cost-effectiveness analysis of camrelizumab plus chemotherapy as first-line treatment for advanced squamous NSCLC in China
by: Taihang Shao, et al.
Published: (2022)

Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
by: Qingli Cui, et al.
Published: (2022)

Is the Scope of Costs Considered in Budget Impact Analyses for Anticancer Drugs Rational? A Systematic Review and Comparative Study
by: Yue Ma, et al.
Published: (2021)

Tislelizumab plus chemotherapy versus pembrolizumab plus chemotherapy for the first-line treatment of advanced non-small cell lung cancer: systematic review and indirect comparison of randomized trials
by: Yimeng Guo, et al.
Published: (2023)

Cost-effectiveness analysis of tislelizumab vs. camrelizumab for the treatment of second-line locally advanced or metastatic esophageal squamous cell carcinoma
by: Pingyu Chen, et al.
Published: (2024)

Predictors of Quality of Life in Patients With Myocardial Infarction Combined With Dyslipidemia
by: Mengran Zhang, et al.
Published: (2021)

Atezolizumab Plus Chemotherapy vs. Chemotherapy in Advanced or Metastatic Triple-Negative Breast Cancer: A Cost-Effectiveness Analysis
by: Xiaoyan Liu, et al.
Published: (2021)

Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy vs. Chemotherapy Alone as First-Line Treatment in Patients With Esophageal Squamous Cell Carcinoma and PD-L1 CPS of 10 or More
by: Zhiwei Zheng, et al.
Published: (2022)

Cost-effectiveness analysis of first-line tislelizumab plus chemotherapy for recurrent or metastatic nasopharyngeal cancer
by: Zhengda Pei, et al.
Published: (2023)

Cost-Effectiveness Analysis of Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China
by: Zhou C, et al.
Published: (2023)

Good Response of Advanced Thymic Carcinoma with Low PD-L1 Expression to Chemotherapy plus Pembrolizumab as First-Line Therapy and to Pembrolizumab as Maintenance Therapy: A Case Report
by: Yoichi Nishii, et al.
Published: (2022)

First-line tremelimumab plus durvalumab and chemotherapy versus chemotherapy alone for metastatic non-small cell lung cancer: a cost-effectiveness analysis in the United States
by: Wenjie Liu, et al.
Published: (2023)

Toripalimab plus chemotherapy in the treatment of metastatic triple-negative breast cancer: a cost-effectiveness analysis
by: Hongfu Cai, et al.
Published: (2024)

Case report: Remarkable response to sintilimab, lenvatinib, and nab-paclitaxel in postoperative metastatic chemotherapy-resistant combined hepatocellular-cholangiocarcinoma
by: Nan Zhou, et al.
Published: (2023)

Tislelizumab plus chemotherapy is more cost-effective than chemotherapy alone as first-line therapy for advanced non-squamous non-small cell lung cancer
by: Xueyan Liang, et al.
Published: (2023)

Effectiveness and safety of pelareorep plus chemotherapy versus chemotherapy alone for advanced solid tumors: a meta-analysis
by: Renxian Xie, et al.
Published: (2023)

Efficacy and safety of sintilimab plus doxorubicin in advanced soft tissue sarcoma: A single-arm, phase II trial
by: Zhichao Tian, et al.
Published: (2022)

Cost-effectiveness analysis of tislelizumab plus chemotherapy as the first-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China
by: Yanhong Liu, et al.
Published: (2024)

Cost-effectiveness analysis of lenvatinib plus pembrolizumab compared with chemotherapy for patients with previously treated mismatch repair proficient advanced endometrial cancer in China
by: Zhiwei Zheng, et al.
Published: (2022)

Economic evaluation of first-line nivolumab plus cabozantinib for advanced renal cell carcinoma in China
by: Hao Wang, et al.
Published: (2022)

The Cost-Effectiveness of Tislelizumab Plus Chemotherapy for Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer
by: Xia Luo, et al.
Published: (2022)

Cost-effectiveness analysis of sugemalimab vs. placebo, in combination with chemotherapy, for treatment of first-line metastatic NSCLC in China
by: Wei Li, et al.
Published: (2022)

Cost-effectiveness of dostarlimab plus chemotherapy for primary advanced or recurrent endometrial cancer
by: Gengwei Huo, et al.
Published: (2024)

Medication adherence with fixed-dose versus free-equivalent combination therapies: Systematic review and meta-analysis
by: Qiran Wei, et al.
Published: (2023)

Maintenance Therapy with Pembrolizumab after Platinum-Doublet Chemotherapy Leading to Hyperprogression in a Patient with Metastatic Bladder Cancer
by: Yangchun Gu, et al.
Published: (2021)